2 Beaten-Down Stocks to Avoid

2025-06-27 08:15:00 ET

Over the past year, Editas Medicine (NASDAQ: EDIT) and Sarepta Therapeutics (NASDAQ: SRPT) , two biotech companies, have encountered severe headwinds that aren't at all related to broader market volatility. Both drugmakers have seen their shares plummet over the trailing-12-month period. However, while investors are supposed to buy low, even at current levels, Editas Medicine and Sarepta aren't attractive stocks to buy.

Let's consider why investors should stay a safe distance away from these two biotech companies.

Image source: Getty Images.

Continue reading